J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
作者信息
Gridelli Cesare, Casaluce Francesca, Sgambato Assunta, Palazzolo Giovanni, Maione Paolo
机构信息
Division of Medical Oncology, 'S. G. Moscati' Hospital, Avellino, Italy.
Division of Medical Oncology, ULSS15 'Alta Padovana', Cittadella, Italy.
出版信息
J Thorac Dis. 2018 Jan;10(1):106-108. doi: 10.21037/jtd.2017.12.76.
Abstract
摘要
相似文献
1
J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?J-ALEX试验会使阿来替尼成为间变性淋巴瘤激酶阳性的初治非小细胞肺癌患者的标准选择吗？
J Thorac Dis. 2018 Jan;10(1):106-108. doi: 10.21037/jtd.2017.12.76.
2
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.阿来替尼对比克唑替尼用于未经治疗的间变性淋巴瘤激酶阳性的非小细胞肺癌亚洲患者（ALESIA）：一项随机的 3 期研究。
Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.
3
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.阿来替尼对比克唑替尼用于治疗 ALK 阳性非小细胞肺癌患者（J-ALEX）：一项开放标签、随机、III 期临床试验。
Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.
4
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于一线治疗间变性淋巴瘤激酶阳性的晚期非小细胞肺癌的成本效果分析。
Pharmacoeconomics. 2018 Apr;36(4):495-504. doi: 10.1007/s40273-018-0625-6.
5
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.更新的疗效和安全性数据以及 EML4-ALK 融合变体对全球 III 期 ALEX 研究中未经治疗的 ALK 阳性晚期非小细胞肺癌中阿来替尼疗效的影响。
J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20.
6
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.分析在 J-ALEX 研究中艾乐替尼对比克唑替尼用于治疗 ALK 阳性非小细胞肺癌的中枢神经系统疗效。
Lung Cancer. 2018 Jul;121:37-40. doi: 10.1016/j.lungcan.2018.04.015. Epub 2018 Apr 17.
7
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.阿来替尼治疗中国未经治疗的 ALK 阳性非小细胞肺癌患者的成本-效果分析。
Adv Ther. 2019 May;36(5):1114-1125. doi: 10.1007/s12325-019-00908-7. Epub 2019 Mar 21.
8
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
9
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.来自 ALECTinib 对比克唑替尼治疗 ALK 阳性非小细胞肺癌患者的随机 III 期 ALEX 研究的患者报告结局。
Lung Cancer. 2019 Dec;138:79-87. doi: 10.1016/j.lungcan.2019.10.002. Epub 2019 Oct 11.
10
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.阿来替尼在间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗中的应用。
Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14.
引用本文的文献
1
Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review.肺腺癌中融合基因对阿来替尼治疗反应良好：一例报告及文献综述
Onco Targets Ther. 2020 Dec 4;13:12515-12519. doi: 10.2147/OTT.S282933. eCollection 2020.
2
Alectinib: A Review in Advanced, ALK-Positive NSCLC.阿来替尼：治疗晚期、ALK 阳性 NSCLC 的研究进展。
Drugs. 2018 Aug;78(12):1247-1257. doi: 10.1007/s40265-018-0952-0.
本文引用的文献
1
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.阿来替尼对比克唑替尼用于治疗 ALK 阳性非小细胞肺癌患者（J-ALEX）：一项开放标签、随机、III 期临床试验。
Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.
2
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.一线塞瑞替尼与铂类化疗用于晚期ALK 重排非小细胞肺癌（ASCEND-4）：一项随机、开放标签、III 期研究。
Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24.
3
Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.克唑替尼和阿来替尼序贯治疗ALK重排阳性非小细胞肺癌患者的无进展生存期和总生存期
Clin Lung Cancer. 2016 Nov;17(6):528-534. doi: 10.1016/j.cllc.2016.05.001. Epub 2016 May 18.
4
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.阿来替尼用于ALK阳性、克唑替尼耐药的非小细胞肺癌：一项单组、多中心、2期试验。
Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19.
5
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.克唑替尼治疗后进展的间变性淋巴瘤激酶阳性非小细胞肺癌患者中阿来替尼的疗效：一项全球 II 期研究。
J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23.
6
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.接受克唑替尼和色瑞替尼序贯治疗的ALK阳性非小细胞肺癌患者的无进展生存期和总生存期
Clin Cancer Res. 2015 Jun 15;21(12):2745-52. doi: 10.1158/1078-0432.CCR-14-3009. Epub 2015 Feb 27.
7
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
8
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.选择性ALK抑制剂阿来替尼在克唑替尼耐药模型中具有强大的抗肿瘤活性。
Cancer Lett. 2014 Sep 1;351(2):215-21. doi: 10.1016/j.canlet.2014.05.020. Epub 2014 Jun 2.
9
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
10
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.克唑替尼（RO5424802）治疗间变性淋巴瘤激酶（ALK）重排的晚期非小细胞肺癌患者（AF-001JP 研究）：一项单臂、开放标签、1 期和 2 期研究。
Lancet Oncol. 2013 Jun;14(7):590-8. doi: 10.1016/S1470-2045(13)70142-6. Epub 2013 Apr 30.
Zotero 插件